Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy
- 30 June 2000
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 26 (3) , 205-227
- https://doi.org/10.1053/ctrv.1999.0162
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- Pharmacokinetics and biodistribution of radiolabelled idoxifene: Prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapyNuclear Medicine and Biology, 1995
- Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trialEuropean Journal Of Cancer, 1992
- New Pharmacokinetic Methods III. Two Simple Tests for “Deep Pool Effect”The Journal of Clinical Pharmacology, 1990
- Pharmacokinetics of toremifeneJournal of Steroid Biochemistry, 1990
- Metabolism of toremifene in the ratJournal of Steroid Biochemistry, 1990
- Review of the pharmacological properties of toremifeneJournal of Steroid Biochemistry, 1990
- Determination of tamoxifen and five metabolites in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1988
- A review of metabolite kineticsJournal of Pharmacokinetics and Biopharmaceutics, 1985